Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States
PharmacoEconomics - Open · 2026-05 · 10 (3) · 457-469
DOI: 10.1007/s41669-026-00643-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift PharmacoEconomics - Open, online erschienen am 06.03.2026. Verfasst von Ahmead Baljoon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Economic, Social and Administrative Pharmacy (ESAP) Department, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Economic, Social and Administrative Pharmacy (ESAP) Department, College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Tallahassee, FL, 32307, USA.
- Independent Researcher, Gainesville, FL, 32606, USA.
- Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, 10920 McKinley Dr., Tampa, FL, 33612, USA. islam.eljilany@hotmail.com.
Zitieren
APA
Baljoon, A., Diaby, V., Suther, S., Dutton, M., Ali, A., & Eljilany, I. (2026). Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States. PharmacoEconomics - Open, 10(3), 457-469. https://doi.org/10.1007/s41669-026-00643-0
Vancouver
Baljoon A, Diaby V, Suther S, Dutton M, Ali A, Eljilany I. Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States. PharmacoEconomics - Open. 2026;10(3):457-469. doi:10.1007/s41669-026-00643-0
BibTeX
@article{Baljoon2026,
author = {Baljoon, Ahmead and Diaby, Vakaramoko and Suther, Sandra and Dutton, Matthew and Ali, Askal and Eljilany, Islam},
title = {Cost-Utility Analysis of Faricimab Versus Aflibercept in Treating Neovascular Age-Related Macular Degeneration (nAMD) in the United States},
journal = {PharmacoEconomics - Open},
year = {2026},
volume = {10},
number = {3},
pages = {457--469},
doi = {10.1007/s41669-026-00643-0}
}
EUVIMED